Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion
Cancer Medicine · 2023-08 · 12 (16) · 16788-16792
DOI: 10.1002/cam4.6300 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 05.07.2023. Verfasst von Martín I Castillo und 20 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Hematología, Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria INCLIVA, Valencia, Spain. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Splicing Factor U2AF. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
In myelodysplastic neoplasms (MDS), the 20q deletion [del(20q)] is a recurrent chromosomal abnormality that it has a high co‐occurrence with U2AF1 mutations. Nevertheless, the prognostic impact of U2AF1 in these MDS patients is uncertain and the possible clinical and/or prognostic differences between the mutation type and the mutational burden are also unknown.
Methods
Our study analyzes different molecular variables in 100 MDS patients with isolated del(20q). Results & Conclusions We describe the high incidence and negative prognostic impact of U2AF1 mutations and other alterations such as in ASXL1 gene to identify prognostic markers that would benefit patients to receive earlier treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Hematología, Hospital Clínico Universitario de Valencia, Instituto de Investigación Sanitaria INCLIVA, Valencia, Spain.
- Servicio de Hematología, Hospital Universitario y Politécnico La Fe, Instituto de Investigación Sanitaria La Fe, CIBERONC - ISCIII, Valencia, Spain.
- CIMA LAB Diagnostics, Universidad de Navarra, CIBERONC - ISCIII, Pamplona, Spain.
- Servicio de Hematología, Consorcio Hospital General Universitario de Valencia, Valencia, Spain.
- Servicio de Hematología y Hemoterapia del Hospital Universitario de Cruces, Barakaldo, Spain.
- Servicio de Hematología, Hospital de la Santa Creu i Sant Pau, Valencia, Spain.
ORCID-Profile: Martín I Castillo
Zitieren
APA
Castillo, M. I., Ribate, V. E., Muñoz, C. M., Santillana, S. G., Taboada, S. E., Casterá, M. E., Abinzano, C. M. J., Barranco, I. A., Nieto, C. R., Pampliega, V. M., Blanco, M. L., de Andrés, Á. S., de Oteyza, P. J., Del Castillo, B. T., Font, G. I., Cayuela, J. A., Díez-Campelo, M., Sánchez, A. R., Vercet, S. C., …, & Grupo Español de Síndromes Mielodisplásicos (GESMD) (2023). Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion. Cancer Medicine, 12(16), 16788-16792. https://doi.org/10.1002/cam4.6300
Vancouver
Castillo MI, Ribate VE, Muñoz CM, Santillana SG, Taboada SE, Casterá ME, et al. Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion. Cancer Medicine. 2023;12(16):16788-16792. doi:10.1002/cam4.6300
BibTeX
@article{Castillo2023,
author = {Castillo, Martín I and Ribate, Villamón E and Muñoz, Calabuig M and Santillana, Sanz G and Taboada, Such E and Casterá, Mora E and Abinzano, Calasanz M J and Barranco, Irigoyen A and Nieto, Collado R and Pampliega, Vara M and Blanco, M L and de Andrés, Álvarez S and de Oteyza, Pérez J and Del Castillo, Bernal T and Font, Granada I and Cayuela, Jerez A and Díez-Campelo, M and Sánchez, Abellán R and Vercet, Solano C and Díaz, Tormo M and Grupo Español de Síndromes Mielodisplásicos (GESMD), Grupo Español de Síndromes Mielodisplásicos (GESMD)},
title = {Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion},
journal = {Cancer Medicine},
year = {2023},
volume = {12},
number = {16},
pages = {16788--16792},
doi = {10.1002/cam4.6300}
}
EUVIMED